Skip to main
MYO

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc has demonstrated a growing reimbursement pipeline, with units increasing from 1,389 in Q4 to 1,669 in Q2, indicating a strengthening demand for its myoelectric orthotics. The company is strategically redirecting growth towards the orthotics and prosthetics market, which is set to account for approximately 22% of revenue in 2024, while also benefiting from the substantial Medicare market. A recent ruling by the CMS to include the MyoPro under Medicare Part B benefits further enhances Myomo's market potential, positioning the company for expansive revenue growth.

Bears say

Myomo has recently revised its 2025 revenue guidance downwards to a range of $40 million to $42 million, significantly lower than the previous estimate of $50 million to $53 million, indicating a decline in financial performance expectations. Additionally, the company has reported a decrease in its backlog of insurance authorized orders to 208, down from 230 in the previous quarter and a peak of 272 in the fourth quarter, reflecting diminished sales momentum. Furthermore, the quality of Myomo's recent marketing efforts and pipeline additions has reportedly been poorer than anticipated, adversely impacting lead generation and conversion rates, which raises concerns about future revenue growth potential.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.